US bill aims to provide exclusivity, other incentives for antibiotic makers
This article was originally published in SRA
Executive Summary
US lawmakers have introduced a bill that could give manufacturers of antibiotics for treating the deadliest and most drug-resistant bacteria an additional five years of data exclusivity protection as well as fast-track status and six-month priority reviews by the Food and Drug Administration1.